AMES, IA -- (Marketwired) -- 12/05/13 --
In the news release, "NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference," issued earlier today by NewLink Genetics Corporation (NASDAQ: NLNK), we are advised by the company that the conference date in the first paragraph should read "Tuesday, December 10, 2013" rather than "Tuesday, December 11, 2013" as originally issued. The headline has also been updated. Complete corrected text follows.
NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference, Tuesday, December 10, 2013
AMES, IA -- Dec 5, 2013 -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference in New York, on Tuesday, December 10, 2013 at 1:35 p.m. ET.
About NewLink Genetics Corporation
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit http://www.linkp.com. Patient information is available at http://www.pancreaticcancer-clinicaltrials.com.
Contact:
Gordon Link
Chief Financial Officer
515-598-2925
glink@linkp.com
Source: NewLink Genetics Corporation
News Provided by Acquire Media
